These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28342075)

  • 21. Boxed warning inconsistencies between drug information resources and the prescribing information.
    Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
    Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Timing of new black box warnings and withdrawals for prescription medications.
    Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
    JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.
    Bian J; Chen B; Hershman DL; Marks N; Norris L; Schulz R; Bennett CL
    J Clin Oncol; 2017 Jun; 35(17):1945-1951. PubMed ID: 28441110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigating drug repositioning opportunities in FDA drug labels through topic modeling.
    Bisgin H; Liu Z; Kelly R; Fang H; Xu X; Tong W
    BMC Bioinformatics; 2012; 13 Suppl 15(Suppl 15):S6. PubMed ID: 23046522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-marketing safety-related regulatory actions on first-in-class drugs: A double-cohort study.
    Ikeda J; Kaneko M; Narukawa M
    J Clin Pharm Ther; 2020 Jun; 45(3):496-502. PubMed ID: 31846100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences between the United States and Japan in labels of oncological drugs.
    Jayaputra K; Ono S
    Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
    Matlock A; Allan N; Wills B; Kang C; Leikin JB
    Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence.
    Kloet MA; Lohr BR; Smithburger PL; Seybert AL; Kane-Gill SL
    J Patient Saf; 2017 Mar; 13(1):25-30. PubMed ID: 24647270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Value of the Black Box Warning in Dermatology.
    Winterfield L; Vleugels RA; Park KK
    J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):e6-e8. PubMed ID: 32236460
    [No Abstract]   [Full Text] [Related]  

  • 33. Atomoxetine use during a period of FDA actions.
    Du DT; Zhou EH; Goldsmith J; Nardinelli C; Hammad TA
    Med Care; 2012 Nov; 50(11):987-92. PubMed ID: 23047788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boxed Warnings and Off-Label Use of Allergy Medications: Risks, Benefits, and Shared Decision Making.
    Greiwe J; Honsinger R; Hvisdas C; Chu DK; Lang DM; Nicklas R; Apter AJ
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3057-3063. PubMed ID: 36064185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-review deadlines and safety problems.
    Carpenter D; Zucker EJ; Avorn J
    N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated approval of drugs: ethics versus efficacy.
    Chary KV; Pandian K
    Indian J Med Ethics; 2017; 2(4):244-247. PubMed ID: 28661403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.